Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $41.08, but opened at $44.24. Supernus Pharmaceuticals shares last traded at $43.41, with a volume of 75,670 shares trading hands.
Wall Street Analyst Weigh In
SUPN has been the topic of several recent analyst reports. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Cantor Fitzgerald increased their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $62.33.
Read Our Latest Stock Report on Supernus Pharmaceuticals
Supernus Pharmaceuticals Stock Up 3.2%
The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -22.08, a PEG ratio of 1.20 and a beta of 0.55. The business has a 50-day moving average of $42.75 and a 200-day moving average of $47.41.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. During the same quarter last year, the firm earned $0.40 EPS. The business’s revenue for the quarter was up 32.4% compared to the same quarter last year. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current year.
Institutional Investors Weigh In On Supernus Pharmaceuticals
Large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $434,871,000. Bank of America Corp DE boosted its holdings in Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after purchasing an additional 193,479 shares in the last quarter. Ashford Capital Management Inc. increased its position in Supernus Pharmaceuticals by 5.4% during the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock worth $33,360,000 after buying an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC increased its position in Supernus Pharmaceuticals by 2.0% during the first quarter. Rice Hall James & Associates LLC now owns 477,416 shares of the specialty pharmaceutical company’s stock worth $24,678,000 after buying an additional 9,530 shares during the last quarter. Finally, Systematic Financial Management LP increased its position in Supernus Pharmaceuticals by 23.6% during the first quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock worth $19,440,000 after buying an additional 71,853 shares during the last quarter.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.
Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.
Read More
- Five stocks we like better than Supernus Pharmaceuticals
- Plugging In: Vertiv Cashes In On AI Demand
- Visa’s Toll Booth Keeps Collecting, But the Price Is Rising
- Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps Growing
- Why Meta Platform’s $100 Billion Financing Plan Is A Boon for Chip Giant Broadcom
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
